John Hudgens
CIK 1486241 · View on SEC EDGAR ↗
First SEC filing: April 5, 2010 · Latest: April 5, 2010
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Aug. 5, 2015 | TCBIO | S | 1,637 | $60.33 | $98,760 | 10,241 Direct | -13.78% | Disposed | -66.1% (price as of 2026-08-20) |
| March 7, 2014 | TCBIO | S | 3,000 | $64.50 | $193,500 | 2,983 Direct | -50.14% | Disposed | -68.2% (price as of 2026-08-20) |
| Oct. 25, 2013 | TCBIO | S | 8,983 | $53.63 | $481,758 | 5,983 Direct | -60.02% | Disposed | -61.8% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Aug. 5, 2015 | TCBIO | Stock Appreciation Rights | Common Stock (4,257) | $22.65 | April 24, 2016 | 4,257 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 9 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| April 5, 2010 | TCBIO | Restricted Stock Units (Common Stock) [F1] | 1,936 | Direct |
| April 5, 2010 | TCBIO | Restricted Stock Units (Common Stock) [F1] | 6,000 | Direct |
| April 5, 2010 | TCBIO | Restricted Stock Units (Common Stock) [F1] | 7,865 | Direct |
| April 5, 2010 | TCBIO | Restricted Stock Units (Common Stock) [F1] | 3,932 | Direct |
| April 5, 2010 | TCBIO | Common Stock | 14,412 | Direct |
| April 5, 2010 | TCBIO | Stock Appreciation Rights→ Common Stock (4,257) | 4,257 | Direct |
| April 5, 2010 | TCBIO | Stock Options→ Common Stock (20,000) | 20,000 | Direct |
| April 5, 2010 | TCBIO | Stock Options→ Common Stock (10,000) | 10,000 | Direct |
| April 5, 2010 | TCBIO | Stock Options→ Common Stock (8,500) | 8,500 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
TCBIO
Chief Risk Officer of the Company| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2018 | $492,667 | — | — | — | — | — | $25,945 | $1,258,764 |
| 2017 | $480,000 | — | — | — | — | — | $25,243 | $1,329,882 |
| 2016 | $455,833 | — | — | — | — | — | $65,051 | $1,444,361 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.